{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:12:11Z","timestamp":1790781131619,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gout is a common inflammatory arthritis with substantial cardiometabolic and renal comorbidity. Although hyperuricemia and baseline kidney function are established predictors of chronic kidney disease (CKD), the prognostic value of long-term gout flare frequency is unclear. This study aimed to examine the association between annual gout flare frequency and the risk of incident CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a large-scale retrospective cohort study using de-identified electronic health record data from the TriNetX Global Collaborative Research Network. Adults with at least one treated gout flare in 2017 and preserved baseline renal function (eGFR\u2009\u2265\u200960 mL\/min\/1.73\u00a0m\u00b2) were included. Exposure was defined by the annual frequency of treated gout flares. The primary outcome was incident CKD stage 3\u20135 or end-stage renal disease (ESRD). To minimize reverse causation, a 180-day lag period was applied before the start of follow-up. Multivariable Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs) for incident CKD over a 7-year follow-up period, adjusting for age, sex, comorbidities (hypertension, diabetes, heart disease, obesity), and urate-lowering therapy use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 29,321 eligible adults, a higher annual gout flare frequency was independently associated with an increased risk of incident CKD in a graded, dose-dependent manner. Compared with individuals experiencing one flare per year, the risk of incident CKD was significantly higher among those with \u2265\u20095 flares per year, with aHRs ranging from approximately 1.20 to 1.46 across follow-up years. In contrast, experiencing two flares per year did not confer a statistically significant increase in risk relative to the reference group. Risk separation was evident by year 3 and persisted throughout the 7-year observation period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Recurrent gout flares are associated with a progressively increased risk of incident CKD, suggesting that flare frequency serves as a pragmatic, patient-centered prognostic marker for long-term renal risk assessment. These findings underscore the importance of optimizing flare prevention and urate-lowering strategies in high-risk populations to potentially mitigate adverse renal outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-04904-2","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:04:39Z","timestamp":1773741879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Gout flare burden as a marker of chronic kidney disease risk"],"prefix":"10.1186","volume":"27","author":[{"given":"Hung-Ping","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peir-Haur","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon Chih-Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"5","key":"4904_CR1","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/rheumatology\/keq363","volume":"50","author":"D Rothenbacher","year":"2011","unstructured":"Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodr\u00edguez LAG. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology. 2011;50(5):973\u201381.","journal-title":"Rheumatology"},{"issue":"24","key":"4904_CR2","doi-asserted-by":"publisher","first-page":"7616","DOI":"10.3390\/jcm13247616","volume":"13","author":"J Timsans","year":"2024","unstructured":"Timsans J, Palom\u00e4ki A, Kauppi M. Gout and hyperuricemia: A narrative review of their comorbidities and clinical implications. J Clin Med. 2024;13(24):7616.","journal-title":"J Clin Med"},{"issue":"2","key":"4904_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41584-021-00725-9","volume":"18","author":"HK Choi","year":"2022","unstructured":"Choi HK, McCormick N, Yokose C. Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nat Rev Rheumatol. 2022;18(2):97\u2013111.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"4904_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/jama.2022.11390","volume":"328","author":"E Cipolletta","year":"2022","unstructured":"Cipolletta E, Tata LJ, Nakafero G, Avery AJ, Mamas MA, Abhishek A. Association between gout flare and subsequent cardiovascular events among patients with gout. JAMA. 2022;328(5):440\u201350.","journal-title":"JAMA"},{"issue":"4","key":"4904_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.kint.2024.05.033","volume":"106","author":"RJ Johnson","year":"2024","unstructured":"Johnson RJ, Mandell BF, Schlesinger N, Mount DB, Botson JK, Abdellatif AA, Rhoades R, Singh JA. Controversies and practical management of patients with gout and chronic kidney disease. Kidney Int. 2024;106(4):573\u201382.","journal-title":"Kidney Int"},{"key":"4904_CR6","doi-asserted-by":"crossref","unstructured":"Kannuthurai V, Gaffo A. Management of patients with gout and kidney disease: a review of available therapies and common missteps. Kidney360. 2023; 2023, 4(9):e1332\u2013e1340.","DOI":"10.34067\/KID.0000000000000221"},{"issue":"4","key":"4904_CR7","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/1756-185X.13266","volume":"21","author":"KH Yu","year":"2018","unstructured":"Yu KH, Chen DY, Chen JH, Chen SY, Chen SM, Cheng TT, Hsieh SC, Hsieh TY, Hsu PF, Kuo CF. Management of gout and hyperuricemia: multidisciplinary consensus in Taiwan. Int J Rheum Dis. 2018;21(4):772\u201387.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"4904_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13075-021-02416-y","volume":"23","author":"HL Pisaniello","year":"2021","unstructured":"Pisaniello HL, Fisher MC, Farquhar H, Vargas-Santos AB, Hill CL, Stamp LK, Gaffo AL. Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review. Arthritis Res therapy. 2021;23(1):130.","journal-title":"Arthritis Res therapy"},{"issue":"2","key":"4904_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3899\/jrheum.191242","volume":"48","author":"W Taylor","year":"2021","unstructured":"Taylor W, Dalbeth N, Saag KG, Singh JA, Rahn EJ, Mudano AS, Chen Y-H, Lin C-T, Tan P, Louthreno W. Flare rate thresholds for patient assessment of disease activity states in gout. J Rhuematol. 2021;48(2):293\u20138.","journal-title":"J Rhuematol"},{"issue":"6","key":"4904_CR10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/acr.25494","volume":"77","author":"LK Stamp","year":"2025","unstructured":"Stamp LK, Frampton C, Stewart S, Petrie KJ, Edwards NL, Gaffo A, Dalbeth N. Relationship Between Gout Flare States and Patient-Reported Outcomes After Allopurinol Initiation. Arthritis Care Res. 2025;77(6):727\u201331.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"4904_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s42466-025-00424-w","volume":"7","author":"E Panagiotopoulos","year":"2025","unstructured":"Panagiotopoulos E, Kotsali-Peteinelli V, Papagiannopoulou G, Theodorou A, Chondrogianni M, Bakola E, Palaiodimou L, Psychogios K, Kargiotis O, Safouris A. Gout flares following acute stroke: a single-center cohort and a systematic review\/meta-analysis. Neurol Res Pract. 2025;7(1):75.","journal-title":"Neurol Res Pract"},{"issue":"1","key":"4904_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/rheumatology\/keab283","volume":"61","author":"R Bajpai","year":"2022","unstructured":"Bajpai R, Muller S, Mallen C, Watson L, Richette P, Hider SL, Roddy E. Onset of comorbidities and flare patterns within pre-existing morbidity clusters in people with gout: 5-year primary care cohort study. Rheumatology. 2022;61(1):407\u201312.","journal-title":"Rheumatology"},{"key":"4904_CR13","doi-asserted-by":"crossref","unstructured":"Russo E, Verzola D, Cappadona F, Leoncini G, Garibotto G, Pontremoli R, Viazzi F. The role of uric acid in renal damage-a history of inflammatory pathways and vascular remodeling. Vessel Plus 2021, 5(15).","DOI":"10.20517\/2574-1209.2021.11"},{"key":"4904_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1136\/annrheumdis-2022-eular.2969","volume":"81","author":"N McCormick","year":"2022","unstructured":"McCormick N, Lu L, Yokose C, Joshi A, Zhang Y, Choi H. Chronic kidney disease and amplification of serum urate impact on gout risk: Population-based study of >\u2009450,000 UK biobank participants. Ann Rheum Dis. 2022;81:109\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4904_CR15","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.7150\/ijms.59698","volume":"18","author":"F-S Yen","year":"2021","unstructured":"Yen F-S, Wei JC-C, Chang C-L, Yang C-C, Hsu C-C, Hwu C-M. Urate-lowering therapy and chronic kidney disease development in patients with gout. Int J Med Sci. 2021;18(12):2599.","journal-title":"Int J Med Sci"},{"issue":"1","key":"4904_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamainternmed.2024.6212","volume":"185","author":"Y Wang","year":"2025","unstructured":"Wang Y, Dalbeth N, Terkeltaub R, Zhang Y, Li X, Zeng C, Lei G, Wei J. Target serum urate achievement and chronic kidney disease progression in patients with gout and kidney disease. JAMA Intern Med. 2025;185(1):74\u201382.","journal-title":"JAMA Intern Med"},{"key":"4904_CR17","unstructured":"TriNetX. (2025). TriNetX Global Health Research Network. Cambridge, MA: Accessed Janunary 7, 2026. TriNetX, LLC. https:\/\/www.trinetx.com"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04904-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04904-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04904-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:19:06Z","timestamp":1781641146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04904-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4904"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04904-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Institutional Review Board of Ditmanson Foundation Chia-Yi Christian Hospital (IRB number: 2025093). The study was conducted in accordance with the principles of the Declaration of Helsinki. As this study utilized de-identified electronic health record data from the TriNetX federated research network, the requirement for informed consent was waived by the ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"258"}}